Figure 5 is a metagraph depicting the effect of SGAs on CYBOCS scores for pervasive developmental disorders. This metagraph pooled three studies with a total of 325 patients that compared three difference SGAs with placebo: aripiprazole, olanzapine, and risperidone. The effect estimate showed a significantly greater decrease in obsessive-compulsive symptoms with use of SGAs than with placebo (MD = -1.71; 95 percent CI, -3.17 to -0.25). Considerable heterogeneity was present (p = 0.14, I2 = 49 percent).

Figure 5SGAs versus placebo on CYBOCS in pervasive developmental disorders

CI = confidence interval; CYBOCS = Children's Yale-Brown Obsessive-Compulsive Scale; df = degrees of freedom; IV = inverse variance; SD = standard deviation; SGA = second-generation antipsychotic

From: Results

Cover of First- and Second-Generation Antipsychotics for Children and Young Adults
First- and Second-Generation Antipsychotics for Children and Young Adults [Internet].
Comparative Effectiveness Reviews, No. 39.
Seida JC, Schouten JR, Mousavi SS, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.